ArticleBMC medicine2023

A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy.

Zude Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.